Zai Lab’s August 6 earnings could reveal whether its 2026 commercial reset is starting to work
Zai Lab reports Q2 2026 results on August 6 as investors assess revenue pressure, COBENFY and TIVDAK launches, and zoci pipeline progress.
Pharma & Biotech
Pharma & Biotech
Why EMA orphan status gives Zai Lab’s zoci more than a regulatory credibility boost
Find out how Zai Lab’s zocilurtatug pelitecan could reshape DLL3-targeted cancer therapy as development risks remain.
Pharma & Biotech
AACR 2026: Can Zai Lab’s zocilurtatug pelitecan change the treatment picture for small cell lung cancer brain metastases?
Read how Zai Lab’s zocilurtatug pelitecan posted strong AACR 2026 data in SCLC brain metastases and NECs, and what it could change next.
Pharma & Biotech
How Boehringer Ingelheim and Zai Lab are advancing a two-pronged DLL3 attack in SCLC
Can dual DLL3 targeting improve SCLC outcomes? Read PDN’s deep analysis of the Boehringer Ingelheim and Zai Lab collaboration today.
Pharma & Biotech
What Zai Lab’s latest oncology data reveal about its long-term positioning in ADC and immunotherapy markets
Zai Lab presents new oncology data at AACR 2026. Discover what its ADC and immunotherapy pipeline could mean for future cancer treatment strategies.